Traduction de «first pharmaceutical » (Néerlandais → Français) :

TERMINOLOGIE

first-pass | eerste hindernis
?

TRADUCTIONS EN CONTEXTE

In 2000, Novartis was among the first pharmaceutical companies to sign the United Nations Global Compact, a set of 10 principles covering environmental issues, human rights, labor standards and anti-corruption efforts.
Avant cela, en 2000, Novartis a été l’un des premiers laboratoires pharmaceutiques signataires du Pacte mondial de l’ONU (The Global Compact), un texte construit autour de dix principes universels privilégiant la protection de l’environnement, les droits humains, les conditions et normes de travail et la lutte contre la corruption.

Pharmaceuticals: +5% (+10% lc) to USD 6.4 billion In a dynamic performance, Pharmaceuticals achieved its highest 2008 quarterly net sales growth rate in local currencies, reflecting the return to growth in the US in the second half of the year after 2007 challenges that lingered into the first half of 2008.
Pharmaceuticals: +5% (+10% en m. l) à USD 6,4 milliards Dans une vigoureuse performance, Pharmaceuticals a réalisé le plus fort taux de croissance trimestriel en 2008 de son chiffre d’affaires net en monnaies locales.

In Pharmaceuticals, ongoing dynamic growth of recently launched products (+91% lc) provided USD 2.0 billion of net sales in the first half of 2009, which represented 15% of net sales compared to 9% in the first half of 2008.
Pharmaceuticals: les produits lancés récemment (+91% en m. l) ont réalisé, grâce à une croissance continue et dynamique, un chiffre d’affaires net d’USD 2,0 milliards au premier semestre 2009; ce qui représente 15% du chiffre d’affaires net de la division contre 9% au premier semestre 2008.

Nine months to September 30 The sustained underlying business expansion in Pharmaceuticals, with net sales rising 11% in local currencies (+4% in US dollars), strengthened the Group’s healthcare portfolio in the first nine months of 2009.
Neuf mois au 30 septembre Au cours des neuf premiers mois de 2009, l’expansion sous-jacente soutenue des activités de Pharmaceuticals, avec une hausse de 11% du chiffre d’affaires net en monnaies locales (m. l) et de 4% en dollars, a renforcé le portefeuille des soins de santé.

Supplementary tables: First half 2010 – Net sales of top 20 pharmaceutical products (unaudited)
Données complémentaires: premier semestre 2010 – Chiffre d’affaires net des vingt premiers produits de la division Pharmaceuticals (non audités)

The key elements of this ambition are, firstly, the provision of efficient and high-quality services and, secondly, compliance with all the legal requirements imposed on the FAMHP (taking account of the revised Belgian pharmaceutical legislation and the European Directives).
The key elements of this ambition are, firstly, the provision of efficient and high-quality services and, secondly, compliance with all the legal requirements imposed on the FAMHP (taking account of the revised Belgian pharmaceutical legislation and the European Directives).

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

The Pharmaceuticals development project PTZ601 (infections) was also halted in the first quarter, resulting in a pre-tax impairment charge of USD 152 million (USD 57 million after release of deferred tax provisions).
Le projet en développement PTZ601 (infections) de Pharmaceuticals aussi été stoppé au premier trimestre, ce qui a entraîné une perte de valeur avant impôts d’USD 152 millions (USD 57 millions après reprises de provisions pour impôts différés).

Pharmaceutical net sales by therapeutic area – First half (unaudited)
Chiffre d’affaires net par domaine thérapeutique – Premier semestre (non audité)